ARIETIS CORPORATION
Boston, MA · Biotech · Private
Urea-depsipeptide (UDEP) antibiotics that activate ClpP protease to kill biofilm-forming bacteria in prosthetic joint infections
- Grants
- $17M
- 14 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Antibiotics for Recalcitrant Infection | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Narrow-spectrum Agents Acting against Helicobacter pylori | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Bactericidal antibiotic for Vancomycin Resistant Enterococci | $1,218,307 | |
| Federal grant | Department of Health and Human Services · Phase II · Antibiotics for Recalcitrant Infection | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Bactericidal antibiotic for Vancomycin Resistant Enterococci | $1,251,577 | |
| Federal grant | Department of Health and Human Services · Phase II · Antibiotics for Recalcitrant Infection | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Bactericidal antibiotic for Vancomycin Resistant Enterococci | $1,248,159 | |
| Federal grant | Department of Health and Human Services · Phase II · A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic | $995,100 | |
| Federal grant | Department of Health and Human Services · Phase II · A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic | $2,986,246 | |
| Federal grant | Department of Health and Human Services · Phase II · A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic | $996,046 | |
| Federal grant | Department of Health and Human Services · Phase II · A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic | $995,100 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Dual-Targeting ClpP Activating Antibiotic | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Dual-Targeting ClpP Activating Antibiotic | $999,619 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Dual-Targeting ClpP Activating Antibiotic | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2206 | Cognosetta, Inc. | — | — |
| 2207 | RJS Biologics L.L.C. | — | — |
| 2208 | TRAVERSE BIOSCIENCES, INC. | — | — |
| 2209 | ARIETIS CORPORATION | — | — |
| 2210 | MBX Biosciences | — | $95M |
| 2211 | TECTARIA BIO LLC | — | — |
| 2212 | PARATEK PHARMACEUTICALS INC | — | $93M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Agents For The Treatment Of Non-replicating Bacteriaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.